Ultimate magazine theme for WordPress.
BTC
$28,656.68
-1.05%
ETH
$1,729.00
-1.29%
LTC
$61.74
-0.39%
DASH
$54.46
-2.98%
XMR
$178.37
-2.74%
NXT
$0.00
-1.05%
ETC
$22.47
+0.77%
DOGE
$0.08
+5.01%
ZEC
$85.33
+1.21%
BTS
$0.01
-0.67%
DGB
$0.01
+0.29%
XRP
$0.38
-1.97%
BTCD
$49.96
+0.01%
PPC
$0.35
-5.36%
CRAIG
$0.01
-1.05%
XBS
$1.68
-0.99%
XPY
$0.00
-1.29%
PRC
$0.00
0%
YBC
$767.43
0%
DANK
$0.01
-1.05%

EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth

EQS-Ad-hoc: Evolva Holding SA / Keyword(s): Financing
Evolva secures additional financing lines to accelerate its growth

27-Dec-2021 / 07:00 CET / CEST
Release of an ad hoc announcement in accordance with art. 53 LR
The publisher is solely responsible for the content of this message.

Reinach, December 27, 2021 – Evolva (SIX:EVE), the Swiss biotech company focused on the research, development and commercialization of products based on nature, today signed an agreement with Nice & Green, a Swiss investment company, to secure additional financing lines until the end 2023 .

The financing lines may be drawn by Evolva in quarterly tranches as needed to support commercial activities and product launches in key markets (pending regulatory approvals), to leverage production efficiencies and expand production capacity, as well as to further development of the company’s product pipeline financing.

Under the agreement, Nice & Green has committed to additional incremental financing lines in the form of convertible bonds on agreed terms up to a maximum principal amount of CHF 12 million until the end of 2023. Together with the currently undrawn financing line of CHF 16 million, Evolva has financing lines totaling CHF 28 million available, if needed. The principal amount of each convertible bond is, at Evolva’s discretion, either redeemable by conversion into common stock of the company or cash. The conversion price is 95 percent of the lowest daily volume-weighted average price for a share on the SIX Swiss Exchange during the 6 trading days immediately prior to conversion.

About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading companies in flavors and fragrances, health ingredients and health protection. Evolva’s employees, half of whom are women, are committed to making the best products that can contribute to health, well-being and sensory pleasure. Learn more at evolva.com and connect with us on LinkedIn.

Disclaimer
This press release contains specific forward-looking statements, eg statements containing terms such as believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause a material difference between the actual results, financial condition, development or performance of the company and those expressed or implied in these statements. Against the background of these uncertainties, readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update or adapt any forward-looking statements to future events or developments.

Contact
Thomas Schneckenburger
Investors and business relations
+41 61 485 2003
+41 79 407 9952
[email protected]

End of ad hoc announcement

Share this news on your FB, Twitter and Whatsapp

File source

News Nation USA: Latest News Headlines
News Nation USA||USA News||Science||Education||Sports||World

Comments are closed.

Situs sbobet resmi terpercaya. Daftar situs slot online gacor resmi terbaik. Agen situs judi bola resmi terpercaya. Situs idn poker online resmi. Agen situs idn poker online resmi terpercaya. Situs idn poker terpercaya.

situs idn poker terbesar di Indonesia.

List website idn poker terbaik.

Game situs slot online resmi